A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder

Clinical Outcomes from an Open-Label Study of Edivoxetine Use in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder

“…Three double-blind studies have been conducted with edivoxetine in adult patients with MDD (Ball et al 2010;Dubé et al 2010;Pangallo et al 2011). Based on the data from healthy adults, edivoxetine appears to be less dependent on the cytochrome P450 (CYP) 2D6 enzyme for metabolism than atomoxetine, and may have less exposure variability in patients with diverse CYP2D6 polymorphisms (Kielbasa et al 2011).…”

Developments in Psychopharmacology for Major Depressive Disorder

“…Another possibility is the selective norepinephrine reuptake inhibitor edivoxetine. While it primarily has been studied for attention deficit hyperactivity disorder, it is also being considered as a potential treatment for major depression; a recent study showed greater symptomatic improvement and higher response and remission rates with edivoxetine compared with placebo in patients with major depression (13).…”

Criticisms of drugs in early development for the treatment of depression: what can be improved?

“…In two clinical trials, the efficacy of edivoxetine monotherapy [17,18] was uncertain when compared to that of placebo for treatment of MDD; the drug also presented safety and tolerability issues such as significant increases in pulse rate and systolic and diastolic blood pressure and a significantly higher rate of discontinuation due to AEs or death. In addition, a recent combination trial of edivoxetine with SSRIs [19] also failed to show superiority to placebo combined with SSRIs.…”